SLS Earnings Summary — Q1 2026

• Net loss for Q1 2026 was $8.41 million, reflecting a sequential increase from the $7.66 million loss in Q4 2025.
• The company remains pre-revenue with no income from product sales, continuing a decade-long historical trend.
• Research & Development expenses rose to $5.13 million, their highest level since Q3 2023, as clinical trials progress.
• Massive shareholder dilution remains a primary concern; basic shares outstanding surged to 172 million, up 96.5% YoY.
• Operating expenses ($9.25 million) are outpacing cash resources, maintaining high dependence on external financing.
• Free Cash Flow for the quarter was a deficit of $8.85 million, worse than the $4.92 million burn in the prior quarter.
• Despite lack of revenue, interest income improved to $0.85 million, providing a minor offset to operating losses.
• The 1-year share count nearly doubled, severely impacting the cost basis for existing long-term retail shareholders.

Management focus remains on the Phase 3 REGAL trial and SLS-009 clinical data; however, current cash runway typically remains under 12 months, requiring frequent capital market access.

Deteriorating

While net losses are nominally lower than some 2023 figures, the accelerating share dilution (up 96.5% YoY) and rising R&D burn without revenue signal increasing financial fragility.

The company's survival is entirely dependent on clinical trial success for Galinpepimut-S (GPS) and the availability of equity financing. Without a commercial product, the financial profile remains high-risk with no clear path to organic profitability.